CAIXY vs REGN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CAIXY · CAIXABANK SA UNSP ADR EA REPR 1/3 ORD EUR0.00$4.33 ▼ 3.78%
REGN · Regeneron Pharmaceuticals$904.35 ▲ 0.16%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CAIXY +26.0%
- REGN +38.8%
Head to head
| Metric | CAIXY | REGN |
|---|---|---|
| Price | $4.33 | $904.35 |
| Change today | ▼ 3.78% | ▲ 0.16% |
| Market cap | $93.44B | $93.55B |
| Return, 3 months | -12.2% | +12.0% |
| Return, year to date | +10.4% | +17.6% |
| Return, 1 year | +23.6% | +38.2% |
| P/E (TTM) | 12.0 | 20.0 |
| P/B | 2.0 | 2.8 |
| P/E percentile vs own 5y | – | 81st |
| Dividend yield | 4.48% | 0.41% |
| Revenue growth (YoY, latest qtr) | – | +36.3% |
| Net profit growth (YoY) | – | +33.5% |
| Gross margin | – | 85.8% |
| Operating margin | – | 30.4% |
| Net margin | – | 28.5% |
| Return on equity | – | 14.9% |
| Analyst target vs. price | – | +6.1% |
| Analyst buy share | – | 70% |
| RSI (14) | 47 | 63 |
| 30-day volatility | 38.6% | 48.7% |
| Max drawdown, 1 year | -21.3% | -25.9% |
| Trend read | Leaning bullish | Strong uptrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- REGN is the largest of the group by market value.
- REGN has returned the most over the past year.
- CAIXY carries the lowest trailing P/E.
- CAIXY pays the highest dividend yield.
- CAIXY has been the calmest stock over the last 30 days.